TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by TG Therapeutics, Inc. on January 8, 2018. The report discloses the entry into a Material Definitive Agreement with Jiangsu Hengrui Medicine Co. ("Jiangsu").
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The primary financial disclosure relates to the terms of the new license agreement:
- Upfront Payment: $1,000,000 payable in Company stock.
- Milestone Payments: Approximately $350,000,000 contingent upon the achievement of certain milestones.
- Royalties: Low double-digit percentages on net sales of licensed products and revenue from sublicenses.
Material Changes
The material change reported is the execution of a global exclusive license agreement. Under this agreement, TG Therapeutics acquired worldwide intellectual property rights for the research, development, manufacturing, and commercialization of products containing Jiangsu's Bruton's Tyrosine Kinase inhibitors (compounds SHR-1459/EBI-1459 or SHR-1266/EBI-1266).
Additionally, the agreement grants Jiangsu a right of first offer prior to TG Therapeutics licensing, selling, developing, or commercializing ublituximab (TG-1101) within China.
Outlook, Risks, and Contingencies
Agreement Terms: The term expires after the last royalty term for the patent rights. Either party may terminate the agreement for breach without remedy, insolvency, or material breach (subject to a 45-day cure period).
Payment Flexibility: Various provisions allow payments to be made in cash or Company stock, though some limit the form of payment.
Disclosure Status: The full text of the agreement is intended to be filed as an exhibit to the Company's next periodic report.
Key Facts for Investor Verification
- Verify the specific milestones required to trigger the $350 million in potential payments.
- Confirm the exact royalty percentage rates defined as "low double digits."
- Review the full agreement text in the next periodic filing for detailed payment conditions and termination clauses.
- Assess the impact of the $1 million stock payment on current share count and dilution.